切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2024, Vol. 17 ›› Issue (04) : 543 -547. doi: 10.3877/cma.j.issn.1674-6902.2024.04.007

论著

SNHG17过表达对非小细胞肺癌切除术预后的意义
韩晓宇1, 李柯育1, 赵志菲1, 高建平2,†()   
  1. 1. 100085　北京，中国人民解放军总医院第二医学中心肿瘤内科
    2. 102600　北京，首都医科大学大兴教学医院胸外科
  • 收稿日期:2024-04-17 出版日期:2024-08-25
  • 通信作者: 高建平
  • 基金资助:
    首都卫生发展科研专项项目(首发2020-4-2085)

Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection

Xiaoyu Han1, Keyu Li1, Zhifei Zhao1, Jianping Gao2,†()   

  1. 1. Department of Medical Oncology, Second Medical Center, General Hospital of the Chinese People′s Liberation Army, Beijing 100085, China
    2. Department of Thoracic Surgery, Daxing Teaching Hospital, Capital Medical University, Beijing 102600, China
  • Received:2024-04-17 Published:2024-08-25
  • Corresponding author: Jianping Gao
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

韩晓宇, 李柯育, 赵志菲, 高建平. SNHG17过表达对非小细胞肺癌切除术预后的意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 543-547.

Xiaoyu Han, Keyu Li, Zhifei Zhao, Jianping Gao. Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 543-547.

目的

分析长链非编码RNA小核仁RNA宿主基因17(small nucleolar RNA host gene 17, SNHG17)表达对非小细胞肺癌(non-small cell lung cancer, NSCLC)切除预后的意义。

方法

选择2020年1月至2022年6月我院收治行NSCLC根治性手术87例患者为对象。术后随访，记录无复发生存期(recurrence-free survival, RFS)和总生存期(overall survival, OS)。采用实时荧光定量PCR法检测组织SNHG17表达水平。

结果

NSCLC组织SNHG17表达(1.85±0.61)高于癌旁正常组织(1.03±0.36)(P<0.05)。TNM分期Ⅰ期SNHG17表达(1.52±0.25)，Ⅱ期(1.83±0.66)(t＝2.283，P<0.05)、Ⅲ期组织SNHG17表达(2.28±0.58)(t＝6.058，P<0.05)，Ⅲ期SNHG17表达较Ⅱ期上调(P<0.05)。SNHG17高表达(≥1.72)43例，SNHG17低表达(<1.72)44例，NSCLC组织SNHG17表达与TNM分期有关(P<0.05)。随访期间复发43例(49.43%)，死亡33例(37.93%)。与SNHG17低表达无复发33例(75.00%)相比，SNHG17高表达者无复发11例(25.58%)少，SNHG17低表达中位RFS时间4.30年长于高表达者2.40年( P<0.05)；SNHG17低表达生存35例(79.55%)大于高表达者19例( 44.19%)，SNHG17低表达中位OS时间5.11年长于高表达者4.28年( P<0.05)。COX回归分析显示SNHG17高表达是NSCLC切除术后复发和预后风险的预测因子(P<0.05)。

结论

SNHG17在NSCLC组织中呈高表达，与NSCLC切除复发和预后高风险密切相关。SNHG17有望作为预测手术切除NSCLC预后的生物标志物。

关键词: 非小细胞肺癌, 小核仁RNA宿主基因17, 手术切除, 预后
Objective

To analyze the prognostic significance of long non-coding RNA small nucleolar RNA host gene 17 (SNHG17) expression in non-small cell lung cancer (NSCLC) resection.

Methods

A total of 87 patients with NSCLC undergoing radical surgery in our hospital from January 2020 to June 2022 were selected as the subjects. After the operation, recurrence-free survival (RFS) and overall survival (OS) were recorded. The expression level of SNHG17 was detected by real-time fluorescence quantitative PCR.

Results

The expression of SNHG17 in NSCLC tissues (1.85±0.61) was higher than that in adjacent normal tissues (1.03±0.36)(P<0.05). TNM stage Ⅰ SNHG17 expression (1.52±0.25), stage Ⅱ (1.83±0.66)(t=2.283, P<0.05), stage Ⅲ SNHG17 expression (2.28±0.58)(t=6.058, P<0.05). The expression of SNHG17 in stage Ⅲ was higher than that in stage Ⅱ(P<0.05). There were 43 cases with high SNHG17 expression (≥1.72) and 44 cases with low SNHG17 expression (<1.72). The expression of SNHG17 in NSCLC tissues was correlated with TNM stage (P<0.05). During the follow-up period, 43 cases (49.43%) relapsed and 33 cases (37.93%) died. Compared with 33 cases (75.00%) with low expression of SNHG17, 11 cases (25.58%) with high expression of SNHG17 had no recurrence, and the median RFS time of low expression of SNHG17 was 4.30 years longer than that of high expression of SNHG17 2.40 years(P<0.05). The survival rate of 35 patients (79.55%) with low expression of SNHG17 was higher than that of 19 patients(44.19%) with high expression. The median OS time of low expression of SNHG17 was 5.11 years longer than that of high expression 4.28 years)(P<0.05). COX regression analysis showed that high expression of SNHG17 was a predictor of recurrence and death after NSCLC resection (P<0.05).

Conclusion

SNHG17 is highly expressed in NSCLC tissues, and high expression is closely related to the risk of recurrence and death of NSCLC. SNHG17 is a promising biomarker for predicting the prognosis of surgically resected NSCLC.

Key words: Non-small cell lung cancer, Small nucleolar RNA host gene 17, Surgical excision, Prognosis
表1 SNHG17表达与NSCLC患者临床特征的关系
临床资料 低表达(n＝44) 高表达(n＝43) χ2值 P值
既往吸烟 27(61.36) 34(79.07) 3.254 0.071
淋巴结转移 38(86.36) 37(86.05) 0.436 0.509
TNM分期     6.407 0.041
Ⅰ 15(34.09) 11(25.58)    
Ⅱ 23(52.27) 16(37.21)    
Ⅲ 6(13.64) 16(37.21)    
EGFR突变 16(36.36) 11(25.58) 1.184 0.277
组织学亚型     0.987 0.610
腺癌 31(70.45) 26(60.47)    
鳞癌 11(25.0) 14(32.56)    
其他 2(4.55) 3(6.98)    
辅助化疗 16(36.36) 13(30.23) 0.368 0.544
辅助放疗 28(63.64) 25(58.14) 0.276 0.599
WBC(×109/L)     2.305 0.129
<10 42(95.45) 37(86.05)    
≥10 2(4.55) 6(13.95)    
NEU(×109/L)     1.913 0.167
<7 41(93.18) 36(83.72)    
≥7 3(6.82) 7(16.28)    
LYM(×109/L)     0.131 0.717
<4 40(90.91) 40(93.02)    
≥4 4(9.09) 3(6.98)    
PLT(×109/L)     0.553 0.457
<300 28(63.64) 24(55.81)    
≥300 16(36.36) 19(44.19)    
EOS(×109/L)     0.131 0.717
<0.50 40(90.91) 40(93.02)    
≥0.50 4(9.09) 3(6.98)    
BAS(×109/L)     0.100 0.752
<0.10 39(88.64) 39(90.70)    
≥0.10 5(11.36) 4(9.30)    
CEA(ng/ml)     0.350 0.554
<5 27(61.36) 29(67.44)    
≥5 17(38.64) 14(32.56)    
NLR     2.212 0.137
<3 19(43.18) 12(27.91)    
≥3 25(56.82) 31(72.09)    
表2 COX回归分析NSCLC切除术后复发的影响因素
影响因素 单因素分析 多因素分析
HR 95%CI P值 HR 95%CI P值
吸烟史 2.095 1.038～4.226 0.039 1.191 0.562～2.526 0.648
淋巴结转移 1.581 0.933～2.679 0.089 － － －
TNM分期≥Ⅲ 1.878 1.012～3.483 0.046 1.467 0.781～2.753 0.233
EGFR突变 0.683 0.346～1.345 0.270 － － －
病理亚型-腺癌 0.948 0.723～1.242 0.699 － － －
辅助化疗 0.584 0.297～1.151 0.120 － － －
辅助放疗 0.538 0.300～0.965 0.038 0.669 0.370～1.210 0.183
WBC≥10×109/L 1.292 0.833～2.002 0.252 － － －
NEU≥7×109/L 1.083 0.920～1.276 0.339 － － －
LYM≥4×109/L 0.652 0.377～1.127 0.126 － － －
PLT≥300×109/L 1.001 0.998～1.004 0.506 － － －
EOS≥0.50×109/L 1.178 0.421～3.292 0.755 － － －
BAS≥0.10×109/L 0.723 0.224～2.332 0.587 － － －
CEA≥5 ng/ml 1.624 0.905～2.912 0.104 － － －
NLR≥3 1.484 0.830～2.654 0.183 － － －
SNHG17高表达 4.218 2.136～8.329 0.001 3.533 1.687～7.399 0.001
1
Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends[J]. Nature Reviews Clinical Oncology, 2023, 20(9): 624-639.
2
Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China[J]. Cancer Commun (Lond), 2022, 42(10): 937-970.
3
Montagne F, Guisier F, Venissac N, et al. The role of surgery in lung cancer treatment: present indications and future perspectives-state of the art[J]. Cancers, 2021, 13(15): 3711-3733.
4
Li N, Wang BX, Li J, et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage Ⅰ to ⅢA non-small cell lung cancer[J]. Cancer, 2022, 128(4): 708-718.
5
Cao Z, Oyang L, Luo X, et al. The roles of long non-coding RNAs in lung cancer[J]. Journal of cancer, 2022, 13(1): 174-183.
6
赵　效，张冰海，李晓霞，等. 长链非编码RNA与非小细胞肺癌相关性的研究进展[J]. 国际生物医学工程杂志，2021, 44(1): 60-64.
7
Ghahramani Almanghadim H, Ghorbian S, Khademi NS, et al. New insights into the importance of long non-coding RNAs in lung cancer: future clinical approaches[J]. DNA and Cell Biology, 2021, 40(12): 1476-1494.
8
Entezari M, Ghanbarirad M, Taheriazam A, et al. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling[J]. Biomed Pharmacother, 2022, 150: 112963.
9
李　渊，王欣鑫，陈世勇，等. 小核仁RNA宿主基因17在癌症进展中的作用研究进展[J]. 解放军医学杂志，2022, 47(9): 932-940.
10
Akbari A, Abbasi S, Borumandnia N, et al. Epigenetic regulation of gastrointestinal cancers mediated by long non-coding RNAs[J]. Cancer Biomark, 2022, 35(4): 359-377.
11
Ma L, Gao J, Zhang N, et al. Long noncoding RNA SNHG17: a novel molecule in human cancers[J]. Cancer Cell Int. 2022, 22(1): 104-115.
12
Cao S, Li H, Li L. LncRNA SNHG17 contributes to the progression of cervical cancer by targeting microRNA-375-3p[J]. Cancer Manag Res, 2021, 13: 4969-4978.
13
Zhu XM, Li L, Ren LL, et al. LncRNA SNHG17 predicts poor prognosis and promotes cell proliferation and migration in hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2021, 25(12): 4219-4227.
14
Chen W, Wang L, Li X, et al. LncRNA SNHG17 regulates cell proliferation and invasion by targeting miR-338-3p/SOX4 axis in esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12(9): 806-814.
15
Tang Z, Feng H, Shu L, et al. Identification of two novel lipid metabolism-related long non-coding RNAs (SNHG17 and LINC00837) as potential signatures for osteosarcoma prognosis and precise treatment[J]. BMC Med Genomics, 2023, 16(1): 115-127.
16
Kay FU, Kandathil A, Batra K, et al. Revisions to the Tumor, Node, Metastasis staging of lung cancer (8 edition): Rationale, radiologic findings and clinical implications[J]. World J Radiol, 2017, 9(6): 269-279.
17
Chevallier M, Borgeaud M, Addeo A, et al. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future[J]. World J Clin Oncol, 2021, 12(4): 217-238.
18
Fois SS, Paliogiannis P, Zinellu A, et al. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer[J]. Int J Mol Sci, 2021, 22(2): 612-630.
19
García-Padilla C, Dueñas Á，García-López V, et al. Molecular mechanisms of lncRNAs in the dependent regulation of cancer and their potential therapeutic use[J]. Int J Mol Sci, 2022, 23(2): 764-784.
20
Luo Y, Lin J, Zhang J, et al. LncRNA SNHG17 contributes to proliferation, migration, and poor prognosis of hepatocellular carcinoma[J]. Can J Gastroenterol Hepatol, 2021, 2021(1): 9990338.
21
Ma T, Zhou X, Wei H, et al. Long non-coding RNA SNHG17 upregulates RFX1 by sponging miR-3180-3p and promotes cellular function in hepatocellular carcinoma[J]. Front Genet, 2021, 11: 607636.
22
Shen S, Liang J, Liang X, et al. SNHG17, as an EMT-related lncRNA, promotes the expression of c-Myc by binding to c-Jun in esophageal squamous cell carcinoma[J]. Cancer Sci, 2022, 113(1): 319-333.
23
Yang Z, Jiang Y, Wang L, et al. Prognosis and biological function of SGOL1 in clear cell renal cell carcinoma: a multiomics analysis[J]. BMC Med Genomics, 2024, 17(1): 60-80.
24
Wu J, Dong G, Liu T, et al. LncRNA SNHG17 promotes tumor progression and predicts poor survival in human renal cell carcinoma via sponging miR-328-3p[J]. Aging (Albany NY), 2021, 13(17): 21232-21250.
25
Zhang Z, Yan Y, Zhang B, et al. Long non-coding RNA SNHG17 promotes lung adenocarcinoma progression by targeting the microRNA-193a-5p/NETO2 axis[J]. Oncol Lett, 2021, 22(6): 818-829.
26
Zhang H, Wang SQ, Wang L, et al. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression[J]. Cell Death Dis, 2022, 13(7): 657-669.
27
Bian Z, Zhou M, Cui K, et al. SNHG17 promotes colorectal tumorigenesis and metastasis via regulating Trim23-PES1 axis and miR-339-5p-FOSL2-SNHG17 positive feedback loop[J]. J Exp Clin Cancer Res, 2021, 40(1): 360-372.
28
Zhao H, Dong H, Wang P, et al. Long non-coding RNA SNHG17 enhances the aggressiveness of C4-2 human prostate cancer cells in association with β-catenin signaling[J]. Oncol Lett, 2021, 21(6): 472-481.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[5] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[6] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[7] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[8] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[9] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[10] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[11] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[12] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[13] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？